论文部分内容阅读
许多疾病可用酶制剂治疗,如先天性酶缺损、高尿酸血症、痛风及白血病等,但由于异性蛋白经非胃肠道途径给入会引起机体抗原抗体反应,长期反复注射后产生过敏症状,而且初用时有效,随着抗体的生成,酶制剂变得无效,从而严重地影响了临床使用。近年来发现可溶性聚合物聚乙二醇单甲醚类(PEG)与蛋白质偶联后,可以达到减少或消除异性蛋白免疫原性的目的。 PEG的通式为CH_3(OCH_2CH_2)_nOH,它本身无免疫原性,是一种不带电荷的线形大分子。其分子中每一个-OCH_2CH_2-可以与3个
Many diseases can be treated with enzymes, such as congenital enzyme deficiency, hyperuricemia, gout and leukemia, but because of heterosexual protein by the non-gastrointestinal route will cause the body antigen-antibody reaction, long-term repeated injection of allergic symptoms, and Initial use effective, with the formation of antibodies, enzymes become ineffective, which seriously affected the clinical use. In recent years, soluble polyethylene glycol monomethyl ether (PEG) has been found to couple with protein to reduce or eliminate the immunogenicity of the heterosexual protein. PEG has the general formula CH_3 (OCH_2CH_2) _nOH, which itself is non-immunogenic and is an uncharged linear macromolecule. Each molecule -OCH_2CH_2- can be combined with three